NEW YORK, June 30 - ActivX Biosciences has received a three-year, $1.1 million Phase II Small Business Innovation Research award from the National Cancer Institute, the company said today.
ActivX will use the grant to build a database of changes in protein activity that result from toxicant exposure. The database, which will allow scientists to compare protein activity profiles of lead compounds with those of known toxic agents, will be used to evaluate candidate drug compounds, the company said.
The company will use its high-throughput protein analysis platform to create the database, and will retain worldwide rights to any inventions made in the course of this project.
The award provides $493,000 for the first year with additional funding of $558,000 scheduled over the second and third years. It follows on a $155,000, six-month Phase I SBIR grant ActivX received in August 2002 to initiate drug toxicity profiling.